P2.09. Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Sampurna Chatterjee
Meta Tag
Speaker Sampurna Chatterjee
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
WCLC 2023 conference
drug combination therapy
EGFR ex20ins non-small cell lung cancer
accelerated approval
patient-derived xenograft (PDX) models
tumor growth inhibition
molecular characterization
synergetic efficacy
Powered By